Tema Neuroscience and Mental Health ETF (MNTL)
| Assets | $10.28M |
| Expense Ratio | 0.75% |
| PE Ratio | 20.46 |
| Shares Out | 440,000 |
| Dividend (ttm) | $0.26 |
| Dividend Yield | 1.08% |
| Ex-Dividend Date | Dec 11, 2024 |
| Payout Frequency | n/a |
| Payout Ratio | 22.11% |
| Volume | 4 |
| Open | 23.81 |
| Previous Close | 23.80 |
| Day's Range | 23.81 - 23.81 |
| 52-Week Low | 19.86 |
| 52-Week High | 27.66 |
| Beta | n/a |
| Holdings | 44 |
| Inception Date | Jan 22, 2024 |
About MNTL
Fund Home PageThe Tema Neuroscience and Mental Health ETF (MNTL) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, concentrating on companies engaged in addressing disorders of the central nervous system and mental health worldwide. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. MNTL was launched on Jan 22, 2024 and is issued by Tema.
Top 10 Holdings
55.47% of assets| Name | Symbol | Weight |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 10.32% |
| Regeneron Pharmaceuticals, Inc. | REGN | 8.08% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 7.74% |
| argenx SE | ARGX | 5.83% |
| Neurocrine Biosciences, Inc. | NBIX | 4.89% |
| Teva Pharmaceutical Industries Limited | TEVA | 4.31% |
| Eli Lilly and Company | LLY | 4.05% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 3.54% |
| Ionis Pharmaceuticals, Inc. | IONS | 3.48% |
| Stryker Corporation | SYK | 3.22% |
Performance
MNTL had a total return of -8.97% in the past year, including dividends. Since the fund's inception, the average annual return has been -4.02%.
News
Tema Announces Liquidation of Two ETFs
NEW YORK--(BUSINESS WIRE)--After careful consideration, Tema ETFs LLC, investment adviser to Tema Luxury ETF and the Tema Neuroscience and Mental Health ETF (the "Funds"), has recommended, and the Boa...
MNTL ETF: Neuroscience & Mental Health ETF
Tema ETFs recently launched the neuroscience and mental health ETF. MNTL ETF is designed to invest in companies at the forefront of combating neurological diseases and psychiatric disorders.